CoChat

Antagonism of IAPs Enhances CAR T-cell Efficacy

Michie, Jessica, Beavis, Paul A., Freeman, Andrew J., Vervoort, Stephin J., Ramsbottom, Kelly M., Narasimhan, Vignesh, Lelliott, Emily J., Lalaoui, Najoua, Ramsay, Robert G., Johnstone, Ricky W., Silke, John, Darcy, Phillip K., Voskoboinik, Ilia, Kearney, Conor J., Oliaro, Jane · 2019 · Cancer Immunology Research
Cited by 99

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute lymphoblastic leukemia and B-cell lymphoma. However, the efficacy of CAR T cells against solid tumors is poor, likely due to tumor-associated immunosuppression. Here, we demonstrated that antagonizing the “inhibitor of apoptosis proteins” with the clinical smac-mimetic, birinapant, significantly enhanced the antitumor activity of CAR T cells in a tumor necrosis factor (TNF)-dependent manner. Enhanced tumor cell death occurred independently of the perforin-mediated granule exocytosis pathway, underscoring the cytotoxic potential of CAR T-cell–derived TNF. Combining CAR T-cell therapy with birinapant significantly reduced established tumor growth in vivo, where either therapy alone was relatively ineffective. Using patient biopsy-derived tumoroids, we demonstrated the synergistic potential of combining CAR T-cell therapy with smac-mimetics. Taken together, we identified CAR T-cell–derived TNF as a potent antitumor effector, which can be further harnessed by smac-mimetics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0428

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 99

Metadata

Authors
Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., Silke, J., Darcy, P. K., Voskoboinik, I., Kearney, C. J., & Oliaro, J.
Venue
Cancer Immunology Research
Published
2019-02-01
Volume
7
Issue
2
Pages
183-192
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2909163111
Cited by
99
References
3
FWCI
4.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antagonism of IAPs Enhances CAR T-cell Efficacy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0428
The paper
Michie, J., Beavis, P. A., Freeman, A. J., Vervoort, S. J., Ramsbottom, K. M., Narasimhan, V., Lelliott, E. J., Lalaoui, N., Ramsay, R. G., Johnstone, R. W., Silke, J., Darcy, P. K., Voskoboinik, I., Kearney, C. J., & Oliaro, J. (2019). Antagonism of IAPs Enhances CAR T-cell Efficacy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.